Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial

Milagritos D. Tapia*, Samba O. Sow, Birahim P. Ndiaye, Khardiata D. Mbaye, Aliou Thiongane, Cheikh T. Ndour, Souleymane Mboup, Julie A. Ake, Babajide Keshinro, Gideon A. Akintunde, Thompson N. Kinge, Guy Vernet, Jean Joel Bigna, Stephen Oguche, Kwadwo A. Koram, Kwaku P. Asante, Wayne R. Hogrefe, Stephan Günther, Abdi Naficy, Iris De RyckMuriel Debois, Patricia Bourguignon, Erik Jongert, William R. Ballou, Marguerite Koutsoukos, François Roman, Senate Amusu, Leo Ayuk, Catherine Bilong, Owusu Boahen, Makhtar Camara, Fadima Cheick Haidara, Daouda Coly, Siry Dièye, David Dosoo, Melanie Ekedi, Irma Eneida Almeida Dos Santos, Seyram Kaali, Afoke Kokogho, Myron Levine, Nick Opoku, Seth Owusu-Agyei, Simon Pitmang, Fatima Sall, Moussa Seydi, Marcelo Sztein, Mathurin Tejiokem, Awa Traore, Marie Astrid Vernet, Abena Kunadu Yawson

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences